Compare AIDX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIDX | NVNO |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.8M |
| IPO Year | 2025 | 2017 |
| Metric | AIDX | NVNO |
|---|---|---|
| Price | $0.62 | $11.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 86.3K | 14.9K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,045,133.00 | $31,243.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $140.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.71 | N/A |
| 52 Week Low | $0.40 | $0.30 |
| 52 Week High | $14.09 | $13.44 |
| Indicator | AIDX | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 54.86 |
| Support Level | $0.52 | $9.66 |
| Resistance Level | $0.70 | $11.26 |
| Average True Range (ATR) | 0.06 | 0.98 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 86.29 | 47.03 |
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.